This article provides details about the Veralto Corporation 4.85% 15-JAN-2032 bond (FINRA:DHR6410395), including its outstanding amount, face value, coupon rate, maturity date, and issuer information. It also offers a company overview of Veralto Corp., highlighting its segments in Water Quality and Product Quality & Innovation.

The American Cancer Society (ACS) recently reaffirmed Abbott's Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options, strengthening Abbott's position in cancer screening. While this endorsement supports Abbott's long-term growth in diagnostics, the company still faces challenges such as stabilizing diagnostics revenue, managing pricing pressure in markets like China, and offsetting declining COVID testing revenue. Abbott's broader investment narrative relies on its ability to convert innovation into steady earnings growth, with new products like Cologuard and Libre Duo glucose sensors playing a key role, but investors should remain aware of potential headwinds like prolonged price pressure from China.

Highview Merger (HVMC) closed Friday at $10.15, a 0.30% increase, as the blank-check company approaches its peak ahead of a potential merger target announcement. The SPAC, which raised $230 million in its August 2025 IPO, holds $235.6 million in marketable securities, equating to about $10.24 per public share. The company's imminent future depends on securing a business combination, which will be the primary driver for its share price beyond its cash value.

This article compiles various trade ideas and technical analyses for Bank of America (BAC/PM) from different traders on TradingView. The analyses include bullish outlooks based on economic recovery and Elliott Wave patterns, as well as bearish predictions stemming from rising wedge formations and potential debt defaults. Traders offer diverse perspectives on future price movements, resistance levels, and entry/exit points for both long and short positions.

A Singaporean swimming-education company, Fitness Champs Holdings Ltd., has dropped a federal lawsuit against Fort Washington-based Bancroft Capital LLC. The lawsuit came after Fitness Champs' stock price collapsed due to alleged market manipulation and a "pump-and-dump" scheme following its IPO. Bancroft Capital, a veteran-owned firm that took Fitness Champs public, was named as a defendant, with allegations focused on its history with previous microcap IPOs that also experienced volatility.

Rice Hall James & Associates significantly reduced its holdings in Establishment Labs during Q1 2026, selling 102,885 shares valued at $7.03 million. This sale indicates a cautious outlook on the company's future growth, despite ESTA's stock price having risen 91.4% over the past year. Analysts maintain varied ratings, with BTIG holding a Buy rating and Citi maintaining a Neutral stance, as the company navigates rapid growth, cash flow pressures, and regulatory challenges in the aesthetic surgery market.

Minnesota has filed a new lawsuit against 3M, alleging ongoing PFAS contamination from its Cottage Grove plant into waters connected to the Mississippi River. This legal action comes years after an $850 million settlement in 2018, with the state claiming 3M disclosed a previously undeclared discharge in 2020 that continues to this day. The lawsuit highlights the public health concerns associated with "forever chemicals" and seeks daily penalties of up to $30,000 per violation, along with a court order for 3M to protect state waters.

This article provides key information and a detailed overview of the EFZ ProShares Short MSCI EAFE ETF. It includes financial statistics such as assets under management, dividend yield, and expense ratio, along with details about its issuer, inception date, and investment strategy. The article also explains that EFZ provides daily inverse exposure to the MSCI EAFE Index and answers frequently asked questions about ETFs and EFZ's specific characteristics.

Delta Air Lines utilizes its Airbus A330-900neos, typically reserved for long-haul routes, for several domestic flights. In June 2026, 30 of these 34 domestic round-trip flights will operate on the transcontinental route between New York JFK and Los Angeles (LAX). The remaining four flights will originate from Delta's Atlanta hub, with three serving Tampa (TPA) and one flying to Minneapolis-St. Paul (MSP).

Neurocrine Biosciences director Leslie V. Norwalk was granted 2,624 non-qualified stock options with an exercise price of $155.83 per share, vesting monthly starting June 27, 2026, and expiring May 27, 2036. Additionally, Norwalk received 1,284 Restricted Stock Units (RSUs) which will fully vest on May 27, 2027. These equity awards are compensation-related grants, not open-market transactions, and are detailed in a recent SEC Form 4 filing.